Based on the cause- effective roles of high hepcidin levels in multiple diseases including anemia of inflammation or renal anemia (Macdougall, 2012; Nakanishi et al., 2015; Weiss et al., 2019), hepcidin inhibitors were developed for potential clinical use and analyzed in several pre-clinical models (Sun et al., 2012; Poli et al., 2014b; Petzer et al., 2018; Pagani et al., 2019). Here, HAMP is linked to anemia (phenotype).